Neurocrine Biosciences valuation

NBIX · NASDAQ · USD

Compare Neurocrine Biosciences
$165.92Change from previous close: +0.37%Absolute change: +$0.61

Close · November 17, 2026

Valuation

The P/E ratio is 24.5. The average price target of 28 analysts is $208.54.

Data as of November 17, 2026

Neurocrine Biosciences compared with similar companies

Neurocrine Biosciences's P/E (trailing 12 months): 24.5, in line with the median of a group of 9 similar companies (24.5).

Neurocrine Biosciences's metrics compared with similar companies
MetricNeurocrine BiosciencesMedian25th–75th percentileBand
P/E (trailing 12 months)24.524.519.3 – 59.4Middle
Forward P/E13.417.214.4 – 30.2Low
EV/EBITDA15.415.414.0 – 17.3Middle
Price/book4.325.273.71 – 10.1Middle
Price/sales4.524.393.06 – 7.18Middle
Gross margin64.7%73.8%64.7% – 80.8%Low
Operating margin26.6%28.7%20.4% – 36.3%Middle
Net margin19.0%19.9%12.2% – 34.3%Middle
ROE20.4%16.0%13.6% – 20.1%High
Debt/equity0.120.390.12 – 2.13Middle

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Neurocrine Biosciences: valuation over time

On the latest fiscal year's earnings (2025), Neurocrine Biosciences's P/E today is 35.4, below the median of its last 7 fiscal years (53.3; between 23.0 and 275.6 from 2019 to 2025). Relative to earnings, the stock costs less than it used to.

Neurocrine Biosciences P/E and dividend yield at each fiscal year end
Fiscal yearPrice at year endEarnings per shareP/E
2025$141.83$4.6730.4
2024$136.50$3.2941.5
2023$131.76$2.4753.3
2022$119.44$1.5676.6
2021$85.17$0.9292.6
2020$95.85$4.1623.0
2019$107.49$0.39275.6
2018$71.41$0.22—
2017$77.59-$1.62—
2016$38.70-$1.63—

TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.

TickerLandia analysisHow it is calculated

Other metrics

Valuation multiples

Market cap
$16.73B
Enterprise value
$16.45B
PEG
0.33
EV/revenue
4.44

Profitability and growth

ROA
12.5%
ROIC
20.2%
Revenue growth (year over year)
41.2%
Earnings growth (year over year)
-3.9%

Financial health

Total cash
$737.9M
Total debt
$451.8M
Current ratio
2.04
Quick ratio
1.72
Altman Z-Score
6.72
Piotroski F-Score
6.00

Dividends

Dividend yield
0.0%
Payout ratio
0.0%
Ex-dividend date
December 29, 1995

Analysts and estimates

Average price target
$208.54
Median price target
$215.00
High price target
$253.00
Low price target
$150.00
Analysts with a price target
28
Consensus
Strong buy
Forward EPS
$12.30
EPS estimate, current year
$10.59

Shares and trading

Beta
0.33
Average volume
1.31M
Shares outstanding
101.22M
Float
99.9M
Institutional ownership
104.9%
Insider ownership
1.1%
Short interest (% of float)
7.6%
Short ratio (days)
4.53